Biblio

Author Title [ Type

] Year

Filters: Author is de Lima, Marcos [Clear All Filters]

Journal Article

Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, et al. Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. 2023.

Ali N, Sharma AArunkumar, de Rezende ACarolina P, Otegbeye F, Latif BMuhammad, Kerbauy MNassif, Cooper BW, Sanchez G, Metheny L, Bal SK, et al. Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022.

Guha A, Dey AKumar, Al-Kindi S, P Miller E, Ghosh A, Banerjee A, Lopez-Mattei J, Desai NR, Patel B, Oliveira GH, et al. Socio-economic Burden of Myocardial Infarction among Cancer Patients. Am J Cardiol. 2020.

Ahmed N, Li L, Rojas P, Covut F, Reese-Koc J, Kolk M, Malek E, Metheny L, O'Brien T, Caimi P, et al. Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplant. 2021.

Anandan A, Kolk M, Ferrari N, Copley M, Driscoll J, Caimi P, Rashidi A, de Lima M, Malek E. Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Nephrology (Carlton). 2020.

Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.

Rosko A, Wang H-L, de Lima M, Sandmaier B, H Khoury J, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, et al. Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia. Am J Hematol. 2016.

Poudel SK, de Lima M, Metheny L. Posttransplant maintenance therapy for acute leukemias. Curr Opin Hematol. 2019.

Denlinger N, Song N-J, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, et al. Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma. Blood Adv. 2024.

Ueda M, Stefan T, Stetson L, Ignatz-Hoover JJ, Tomlinson B, Creger RJ, Cooper B, Lazarus HM, de Lima M, Wald DN, et al. Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. Front Oncol. 2020;10:327.

Wang J, Sanati F, Firoozmand A, Fu P, Kolk M, Reese-Koc J, de Lima M, Boughan K, Cooper B, Caimi P, et al. Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens. Front Oncol. 2023;13:1186532.

Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580-5588.

Chan WKeung, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, et al. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Exp Hematol Oncol. 2023;12(1):79.

Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. 2022.

Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.

H Deeg J, de Lima M. Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2013;11(10):1227-33.

Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. J Clin Oncol. 2013.

DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.

Jurdi NEl, Filali-Mouhim A, Salem I, Retuerto M, Dambrosio NMargaret, Baer L, Lazarus HM, Caimi P, Cooper B, Tomlinson B, et al. Gastrointestinal Microbiome and Mycobiome changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. Biol Blood Marrow Transplant. 2019.

Søraas A, Matsuyama M, de Lima M, Wald D, Buechner J, Gedde-Dahl T, Søraas CLund, Chen B, Ferrucci L, Dahl JArne, et al. Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells. Aging Cell. 2019:e12897.

Deol A, Sengsayadeth S, Ahn KWoo, Wang H-L, Aljurf M, Antin JHarry, Battiwalla M, Bornhäuser M, Cahn J-Y, Camitta B, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.

Caimi PF, William BM, Silva CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, et al. Comparison of two BCNU - containing regimens in the Rituximab era. Excellent outcomes even in poor risk patients. Biol Blood Marrow Transplant. 2015.

de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, et al. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018.

Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, Agrawal V, A Al-Homsi S, Assal A, Bacher U, et al. Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.

Dharmavaram G, Cao S, Sundaram S, Ayyapan S, Boughan K, Gallogly M, Malek E, Metheny L, Tomlinson B, Otegbeye F, et al. Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models. Am J Hematol. 2020.

Pages